Geert_Oct.md 2.8 KB

On the Cusp of Vaccine Schedule

Introduction

  • Immune response of the host
  • Fast and large-scale immune escape
  • Immune system put pressure on neutralizing epitopes of spike protein
    • Direct consequence of mass-vaccination
    • Result of lower neutralizability of the virus
  • New observations: Antibodies directed to S no longer target the same relative epitopes
  • S Ab now being directed against non-neutralizing epitopes of the spike
    • N-terminal domain
  • These epitopes contrast with localized epitopes in RBD. Less-neutralizing epitopes are more conserved (more shared among variants)
  • In order for Virus to overcome immune pressure - large-scale immune escape
  • Hurdle by virus to overcome immune pressure on conserved or non-neutralizing epitopes - many mutations
  • Current omicron variants are quite different from one another - Why has the immune pressure changed such that it is no longer directed at the RBD, but at the less-variable, more conserved domains within the spike protein (N-terminal)

Immune-Refocusing

  • Focusing on new epitopes
  • Rapid breakthrough infections (consecutive) in the presence of vaccinal antibodies which cannot recognize the neutralizing epitopes
  • Still bind: other epitopes that were not able to provoke a response (due to being out-competed by the other epitopes that the Ab would previously bind to, but are now too differentiated to allow that binding to take place).
  • These new epitopes will re-call memory B cells that were previously primed for RBD epitopes that neutralize virus
    • New Ab production for a usage which doesn't neutralize
    • Putting this epitope under immune pressure will cause selections of mutations that overcome this pressure
    • Suggestions that antibodies that are recalled have high-affinity for conserved epitopes
    • Suboptimal immunity which does not neutralize: how does it compensate?
    • High-affinity can still work to some degree, but it disappears quickly

Newer Epitopes

  • The way to escape is by changing into epitopes with higher specificity to avoid conserved patterns
  • Observed selection of mutations that have specific epitopes with lower neutralizability
  • New epitope, having escaped immune response, will not be well-recognized by pre-existing antibodies
  • Ab will still bind to the mutated epitope, but no neutralization
  • Immune system still produces the same non-neutralizing antibodies
  • Resulting virus will be more infectious
  • Convergence of epitopes towards more Wuhan-like epitopes, whereas initial variants had epitopes that were very different from Wuhan
  • New epitopes very similar to Wuhan's specific epitopes, just not those that are conducive to neutralization
  • Incorporating amino acids that were responsible for enhanced infectiousness of Beta/Gamma/Delta
  • RBD evolving towards hybrid status - combining several aminos to enhance infectiousneses